Jasper Therapeutics, Inc., was incorporated in Delaware on August 13, 2019. The company is a clinical-stage biotechnology company focused on treatments for hypertrophy and hematopoietic stem cells. The company focuses on the development and commercialization of safer and more effective therapeutic drugs for the treatment of diseases such as chronic spontaneous urticaria, low to moderate risk myelodysplastic syndrome, as well as novel conditioning regimens for stem cell transplantation and in vitro gene therapy, a technology for genetically manipulating cells in vitro before transplantation. 

JSPR

JSPR Profile